FADS2: A Potential Drug Target and Biomarker (G9415)

Target Name: FADS2

NCBI ID: G9415

FADS2

FADS2: A Potential Drug Target and Biomarker

Fatty acid oxidation enzyme 2 (FADS2) is a gene that encodes a protein involved in the metabolism of fatty acids. FADS2 is a key enzyme in the 螖6 fatty acid oxidation pathway, which is a critical pathway for the production of omega-3 and omega -6 fatty acids in the body. FADS2 plays a crucial role in the conversion of omega-3 fatty acids, such as EPA and DHA, to their more potent forms, which are essential for various physiological processes, including brain function, inflammation, and pain management.

The 螖6 fatty acid oxidation pathway is a complex metabolic pathway that involves multiple enzymes, including FADS2. This pathway is critical for the production of omega-3 and omega-6 fatty acids, which are essential for various physiological functions. The production of omega- 3 fatty acids is primarily done by the conversion of n-3 fatty acids, such as EPA and DHA, to their more potent forms through the FADS2 enzyme.

FADS2 is a key enzyme in the 螖6 fatty acid oxidation pathway that converts omega-3 fatty acids to their more potent forms.

FADS2 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and peripheral tissues. It is a member of the superfamily of NAD+-dependent enzymes, which are involved in various cellular processes, including metabolism, redox reactions , and signaling pathways. FADS2 is characterized by its NAD+ dependence and its ability to convert omega-3 fatty acids to their more potent forms.

FADS2 has been implicated in various physiological processes, including brain function, inflammation, and pain management. The production of omega-3 fatty acids is primarily done by the conversion of n-3 fatty acids, such as EPA and DHA, to their more potent forms through the FADS2 enzyme. This suggests that FADS2 may be involved in the regulation of fatty acid metabolism and the production of omega-3 and omega-6 fatty acids.

FADS2 may also be involved in the regulation of inflammation and pain management. The production of omega-3 fatty acids is known to have anti-inflammatory effects, which may be due to their ability to modulate the production of pro-inflammatory cytokines. Additionally, the production of omega-6 fatty acids, such as arachidonic acid, is known to contribute to pain management, and FADS2 may be involved in the regulation of this pathway.

FADS2 is also known to be involved in the production of brain-derived neurotrophic factor (BDNF), which is a protein that is involved in the regulation of brain function and the development of neurodegenerative diseases. The production of BDNF is known to be dependent on fatty acid metabolism and the FADS2 enzyme may be involved in this process.

In conclusion, FADS2 is a protein that is involved in the 螖6 fatty acid oxidation pathway and plays a crucial role in the production of omega-3 and omega-6 fatty acids. The FADS2 enzyme has been implicated in various physiological processes, including brain function , inflammation, and pain management. Given its involvement in these processes, FADS2 may be a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of FADS2 in these processes and to develop effective therapies that target this enzyme .

Protein Name: Fatty Acid Desaturase 2

Functions: Involved in the biosynthesis of highly unsaturated fatty acids (HUFA) from the essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3) precursors, acting as a fatty acyl-coenzyme A (CoA) desaturase that introduces a cis double bond at carbon 6 of the fatty acyl chain. Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma-linoleate (GLA) (18:3n-6) and stearidonate (18:4n-3), respectively (PubMed:12713571). Subsequently, in the biosynthetic pathway of HUFA n-3 series, it desaturates tetracosapentaenoate (24:5n-3) to tetracosahexaenoate (24:6n-3), which is then converted to docosahexaenoate (DHA)(22:6n-3), an important lipid for nervous system function (By similarity). Desaturates hexadecanate (palmitate) to produce 6Z-hexadecenoate (sapienate), a fatty acid unique to humans and major component of human sebum, that has been implicated in the development of acne and may have potent antibacterial activity (PubMed:12713571). It can also desaturate (11E)-octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 6 generating (6Z,11E)-octadecadienoate (By similarity). In addition to Delta-6 activity, this enzyme exhibits Delta-8 activity with slight biases toward n-3 fatty acyl-CoA substrates (By similarity)

The "FADS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FADS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets